Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib

Table 1 Baseline characteristics with age, gender, histology including tumor differentiation and Child-Pugh score.

Patient	Age	Gender	Histology^a	Histological differentiation^b	Child-Pugh
1	58	male	HCC	+	A
2	59	male	HCC	+	A
3	65	male	HCC	-	B
4	72	male	HCC	++	A
5	65	male	HCC	++	A
6	65	male	HCC/CC	+/-	-^c
7	67	male	HCC	+	B
8	63	female	HCC	++	A
9	71	male	HCC	++	A
10	65	male	HCC	++	A
11	43	male	HCC	++	A
12	77	male	HCC	+	A
13	54	male	HCC	+	A
14	65	male	HCC	++	A
15	66	male	HCC	+	A
16	65	male	HCC	-	A
17	61	male	HCC	+	A
18	76	male	HCC	-	A
19	59	male	HCC	-	B
20	65	male	HCC	n.d.^d	A
21	69	male	HCC	+	A

aHCC/CC means a tumor with characteristics of both, hepatic and biliary differentiation.
bHistological differentiation: (++) good, (+) moderate and (-) poor tumor differentiation type.
cNo cirrhosis according to the histology of the liver.
dNo histology available; however, AFP value 1.591 μg/l and typical noninvasive HCC criteria
according to current imaging guidelines.

ISSN: 1471-2407